Table 1.
Treatment Group | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 |
---|---|---|---|---|---|---|
15.8 mg group as reference group (primary analysis): | ||||||
5.2 mg/g | 0 (−0.48, 0.48) | 0.29 (−0.2, 0.77) | 0.01 (−0.47, 0.5) | 0.13 (−0.36, 0.62) | 0.14 (−0.36, 0.63) | 0.01 (−0.48, 0.49) |
2.4 mg/g | 0.01 (−0.47, 0.5) | 0.34 (−0.15, 0.83) | 0.08 (−0.41, 0.58) | 0.24 (−0.26, 0.73) | 0.37 (−0.13, 0.87) | 0.22 (−0.27, 0.71) |
1.3 mg/g | 0.2 (−0.28, 0.68) | 0.52 (0.03, 1) | 0.25 (−0.24, 0.73) | 0.16 (−0.34, 0.65) | 0.22 (−0.27, 0.71) | 0.18 (−0.3, 0.67) |
0.4 mg/g | 0.1 (−0.39, 0.59) | 0.36 (−0.13, 0.85) | 0.11 (−0.39, 0.6) | 0.28 (−0.22, 0.77) | 0.34 (−0.16, 0.83) | 0.18 (−0.32, 0.67) |
0.4 mg/g (HT) | 0.11 (−0.38, 0.59) | 0.51 (0.03, 0.99) | 0.23 (−0.25, 0.72) | 0.65* (0.16, 1.14) | 0.33 (−0.16, 0.82) | 0.12 (−0.36, 0.6) |
Usual Brand group as reference group (secondary analysis): | ||||||
15.8 mg/g | −0.06 (−0.55, 0.42) | −0.04 (−0.53, 0.45) | −0.14 (−0.63, 0.35) | −0.16 (−0.65, 0.33) | −0.43 (−0.92, 0.06) | −0.2 (−0.69, 0.29) |
5.2 mg/g | −0.07 (−0.55, 0.42) | 0.25 (−0.24, 0.73) | −0.13 (−0.62, 0.36) | −0.03 (−0.52, 0.46) | −0.3 (−0.79, 0.2) | −0.19 (−0.68, 0.29) |
2.4 mg/g | −0.05 (−0.53, 0.44) | 0.3 (−0.18, 0.79) | −0.06 (−0.55, 0.44) | 0.08 (−0.42, 0.57) | −0.06 (−0.56, 0.44) | 0.02 (−0.47, 0.51) |
1.3 mg/g | 0.14 (−0.34, 0.62) | 0.48 (0, 0.96) | 0.1 (−0.38, 0.59) | 0 (−0.49, 0.49) | −0.21 (−0.7, 0.28) | −0.02 (−0.5, 0.47) |
0.4 mg/g | 0.04 (−0.45, 0.52) | 0.32 (−0.17, 0.81) | −0.04 (−0.53, 0.46) | 0.12 (−0.38, 0.61) | −0.09 (−0.59, 0.4) | −0.02 (−0.52, 0.47) |
0.4 mg/g (HT) | 0.04 (−0.44, 0.52) | 0.47 (−0.01, 0.95) | 0.09 (−0.39, 0.57) | 0.49 (0.01, 0.97) | −0.1 (−0.59, 0.38) | −0.08 (−0.56, 0.4) |
indicates p < 0.01.
Mean differences (95% confidence interval) are reported.